1 in 35 Booster Recipients Suffered Vax-Related Heart Damage: Bombshell Study
“mRNA-1273 booster vaccination-associated elevation of markers of myocardial injury occurred in about one out of 35 persons (2.8%), a greater incidence than estimated in meta-analyses of hospitalized cases with myocarditis (estimated incidence 0.0035%) after the second vaccination,” the researchers wrote in the paper, published by the European Journal of Heart Failure.
In a generally healthy population, the level would be about 1 percent, the researchers said.
The group experiencing the adverse effects was followed for only 30 days, and half still had unusually high levels of high-sensitivity cardiac troponin T, an indicator of subclinical heart damage, at follow-up.
The long-term implications of the study remain unclear as little research has tracked people over time with heart injury after messenger RNA vaccination, which is known to cause myocarditis and other forms of heart damage.
“According to current knowledge, the cardiac muscle can’t regenerate, or only to a very limited degree at best. So it’s possible that repeated booster vaccinations every year could cause moderate damage to the heart muscle cells,” University Hospital Basel professor Christian Muller, a cardiologist and the lead researcher, said in a statement.
Moderna did not respond to a request for comment.
None of the patients experienced a major adverse cardiac event, such as heart failure, within 30 days of booster vaccination, and none had electrocardiogram changes.
The people with elevated levels were advised to avoid strenuous exercise, which may have mitigated more serious problems, the researchers said.
No imaging was done to examine the participants’ hearts, despite imaging being recommended by many cardiologists in cases of suspected vaccine-induced myocarditis.
It’s possible that imaging would have revealed inflammation, which could cause scarring or irregular heartbeat, Dr. Andrew Bostom, a heart expert in the United States who was not involved in the research, told The Epoch Times.
Dr. Anish Koka, an American cardiologist, said that the findings were “super useful to see how ‘cardioactive’ the booster is” but that it was hard to say how significant the elevated troponin levels were, particularly without a comparison to baseline levels. “There is really nothing clinically concerning at 30 days to report,” he said on Twitter.
Study Methods
Researchers posited that the incidence of vaccine-associated heart injury was more prevalent than previously thought following messenger RNA booster vaccination because of a lack of symptoms or mild symptoms.
They defined injury as a sharp increase in high-sensitivity cardiac troponin T on the third day after vaccination without evidence of an alternative cause. The levels of cardiac troponin had to hit the upper limit of normal, 8.9 nanograms per liter in women and 15.5 nanograms per liter in men.
All workers at the University Hospital Basel scheduled to receive a Moderna booster for the first time were offered a chance to participate in the study, unless they experienced a cardiac event or underwent heart surgery within 30 days of vaccination. The workers received a booster, which is half the dosage level of the primary series shots, from Dec. 10, 2021, to Feb. 10, 2022. The cohort ended up being 777 workers, including 540 females. The median age was 37 years.
Among the participants, 40 had elevated levels of cardiac troponin. Alternative causes were identified in 18. For the other 22, the researchers determined they had “vaccine-associated myocardial injury.” The median age of the 22 was 46. All but two were women, making the percentage of women with elevated levels higher than the percentage of men (3.7 percent versus 0.8 percent), which contrasts with most of the previous literature on vaccine-induced myocarditis. That could stem from women receiving a higher vaccine dose per body weight, the researchers said.
Baseline levels were not recorded because the hospital’s COVID-19 task force and the researchers decided that the study “should interfere as little as possible with the motivation of the hospital staff to obtain the mRNA-1273 first booster vaccination and the logistics of booster vaccination itself.”
None of the people with elevated markers had a history of heart disease. While half experienced symptoms, most symptoms were nonspecific like fever. Two participants suffered from chest pain. And two, according to the Brighton Collaboration case definition, likely suffered myocarditis.
Testing was done for high-sensitivity cardiac troponin T because of its sensitivity.
“This marker is extremely sensitive—with other methods such as MRI we wouldn’t have been able to detect any damage to the cardiac muscle, as it only becomes visible once the damage there is about three to five times greater,” Dr. Muller said.
The researchers were not able to figure out the mechanism for the vaccine hurting the heart muscle.
The authors reported some conflicts of interest, including Dr. Muller reporting grants from drugmakers such as Novartis and Roche. The study was funded by the University of Basel and the University Hospital Basel.
Limitations include the lack of baseline levels and lack of imaging.
Previous Findings, and Pending Study
Several other prospective studies examine myocarditis following Pfizer vaccination.
In Thailand, researchers found that 29 percent of 301 adolescents developed cardiovascular effects, including chest pain, after a second Pfizer dose. Seven were diagnosed with heart inflammation.
In Taiwan, researchers established baseline electrocardiogram levels before a second Pfizer dose and recorded abnormal results following the administration in one percent of 4,928 primary school students. That included five students diagnosed with myocarditis or an abnormal heartbeat.
In Israel, a study of 324 health care workers with a median age of 51 who received a second Pfizer booster identified two cases of vaccine-induced heart injury on day three.
Other recent studies have confirmed that vaccine-induced myocarditis can kill, including a South Korean study that ruled out all other possible causes for eight sudden deaths following messenger RNA vaccination. Myocarditis was not suspected as a clinical diagnosis or cause of death before autopsies were performed, researchers said.
The Swiss researchers said more prospective studies are needed to examine post-vaccination heart injury. Long-term problems from the injuries, they stressed, remain unclear.
Moderna was required by U.S. authorities to conduct a prospective study to assess the incidence of subclinical myocarditis following a booster among adults, with a projected completion date of June 30, 2023. Neither the U.S. Food and Drug Administration (FDA) nor Moderna have disclosed the results of the study as of yet.
Pfizer was required to conduct a similar study, with results due on Dec. 31, 2022, but the FDA changed the end date at the request of Pfizer.
Reposted from: https://www.theepochtimes.com/health/subclinical-heart-damage-more-prevalent-than-thought-after-moderna-vaccination-study-5423864
The Incidence of Myocarditis and Pericarditis in Post COVID-19 Unvaccinated Patients - A Large Population-Based Study
However, a Retrospective cohort study of 196,992 adults after COVID-19 infection in Israel between March 2020 and January 2021 concluded that "We did not observe an increased incidence of neither pericarditis nor myocarditis in adult patients recovering from COVID-19 infection." (J Clin Med 2022)
Other Related Studies
A study out of Massachusetts by Yonker and colleagues explored the significance of vaccine-induced spike protein. The researchers collected blood from 16 adolescent and young adult patients hospitalized with postvaccine myocarditis. They used these blood samples to compare the patients’ immune profiles to those of 45 healthy, age-matched control patients who had also received the vaccine. Three quarters of the myocarditis patients had developed the pathology after the second dose. The researchers did not include a control group of unvaccinated individuals.
Myocarditis Not Recovered in 80 Percent at 6 Months After Vaccination
Barmada et al (2023) studied a clinical cohort consisting of 23 patients hospitalized for vaccine-associated myocarditis and/or pericarditis. The cohort was predominately male (87 percent) with an average age of 16.9 plus/minus 2.2 years (ranging from 13 to 21 years). Patients had largely noncontributory past medical histories and were generally healthy before vaccination. Most patients had symptom onset 1 to 4 days after the second dose of the BNT162b2 mRNA vaccine.
Six patients either first experienced symptoms after a delay of more than seven days after vaccination or were incidentally positive for SARS-CoV-2 by polymerase chain reaction (PCR) testing upon hospital admission—these six patients were thus excluded from further analyses, although they potentially reflect the breadth of clinical presentations of vaccine-associated myopericarditis.
The remaining cohort of 17 patients showed no evidence of recent prior SARS-CoV-2 infection, with antibodies to spike (S) protein but not to nucleocapsid (N) protein and negative nasopharyngeal swab reverse transcription quantitative PCR at hospital admission.While the authors clearly show high levels of inflammatory markers, the follow-up MRI scans showed only 20 percent had resolved their abnormalities (late gadolinium enhancement) at over six months (199 days).
Post-vaccination myocarditis, a form of heart inflammation, was identified in a subset of people who died “unexpectedly” at home within 20 days of receiving a COVID-19 vaccine. Researchers analyzed autopsies that had been performed on the people and conducted additional research, including studying tissue samples.
Researchers started with a group of 35, but excluded 10 from further analysis because other causes of death were identified. Of the remaining 25, researchers identified evidence of myocarditis in five.
All of the five people received a Moderna or Pfizer vaccine within seven days of their death, with a mean of 2.5 days. The median age was 58 years. None of the people had COVID-19 infection prior to being vaccinated and nasal swabs returned negative.
Autopsy findings combined with the lack of evidence of other causes of death and how the vaccination happened shortly before the deaths enabled researchers to say that for three of the cases, vaccination was the “likely cause” of the myocarditis and that the cardiac condition “was the cause of sudden death.”
In one of the other cases, myocarditis was believed to be the cause of death but researchers detected a herpes virus, an alternative explanation for the incidence of heart inflammation. The remaining case did not include an alternative explanation for the myocarditis but the researchers said the impact of the inflammation was “discrete and mainly observed in the pericardial fat.” They classified the two cases as possibly caused by vaccination.
Limitations included the small cohort size.
COVID-19 Vaccine Myocarditis Research Wins 2023 Most Popular Preprints Award
We’re thrilled to announce that Dr Peter McCullough, won first place on Preprints.org for a study he co-authored on vaccine-induced myocarditis.Preprints.org is a vital platform for the early dissemination of scholarly research before standard peer review and publication in scientific journals. By allowing research findings to be shared early with the scientific community, Preprints.org facilitates scientific communication and collaboration, enabling researchers to receive feedback and engage with the broader scientific community.
Autopsy Proven Fatal COVID-19 Vaccine-Induced Myocarditis claimed the top spot in the Medicine and Pharmacology category, specifically focusing on cardiac and cardiovascular systems. This research paper delves into a critical issue surrounding COVID-19 vaccination — the potential risk of myocarditis, particularly in cases where it leads to fatal outcomes.
Dr. Peter McCullough Shares Concerning Data on the Long-Term Prognosis for Vaccine-Induced Myocarditis
Treatment protocol for Vaccine induced myocarditis/pericarditis
- ACE inhibitor/ARB, together with carvedilol as tolerated to prevent/limit progressive decline in cardiac function.
- Colchicine in patients with pericarditis – 0.6 mg/day orally; increase to 0.6 mg twice daily if required. Reduce dose if patients develop diarrhea. Monitor white blood cell count. Decrease dose with renal impairment.
- Magnesium to reduce the risk of serious arrhythmias (A starting dose of 100 to 200 mg daily is suggested, increasing the dose as tolerated up to 300 mg (females) to 400 mg daily).
- Coenzyme Q (CoQ) 200-400mg/day. (R, R, R)
- Omega-3 fatty acids – EPA/DHA 2-4 g/day (R). Increase dose slowly as tolerated.
- Resveratrol/flavanoid combination for its anti-inflammatory and antioxidant properties.
- Referral to a cardiologist or ER in case of persistent chest pain or other signs and symptoms of cardiac events are observed.
Resources for Those Injured by the COVID Jab
So, the primary task to prevent and/or address post-jab injuries is to eliminate the spike protein. Ivermectin and hydroxychloroquine bind to and facilitate the removal of spike protein. According to McCullough, nattokinase, bromelain and curcumin also help degrade the spike protein.
FLCCC I-Recover Protocol: Post Vaccine Treatment Protocol (2024)
The Wellness Company’s Spike Support Formula
These ingredients are known for their ability to dissolve spike protein, prevent it from binding to cells, and repair tissue.
Recommended to maintain daily health for anyone exposed to COVID, vaccines, or shedding – and may help your body repair itself and remain at optimal health.
Note: To get 10% OFF, please use this coupon code: ONEDAYMD
.png)
Comments
Post a Comment